Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.39 |
| ▸ | PPARA | Q07869 | 7/20 | 0.39 |
| ▸ | PPARD | Q03181 | 6/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4522978 | 0.92 | PPARG (0.37) | PPARGPPARAPPARDF10HTR6 | |
| SCHEMBL4535048 | 0.92 | PPARG (0.37) | PPARGPPARAPPARDF10HTR6 | |
| SCHEMBL4528728 | 0.88 | PPARG (0.39) | PPARGPPARAPPARDF10HTR6 | |
| SCHEMBL4532915 | 0.86 | PPARG (0.33) | PPARGPPARAPPARDOPRK1 | |
| SCHEMBL4516479 | 0.83 | ALDH1A1 (0.39) | PPARGPPARAPPARDHTR6ALDH1A1 | |
| SCHEMBL4534420 | 0.83 | ALDH1A1 (0.39) | PPARGPPARAPPARDHTR6ALDH1A1 | |
| SCHEMBL4526752 | 0.83 | F10 (0.54) | PPARGPPARAPPARDF10HTR6 | |
| SCHEMBL4523344 | 0.81 | PPARG (0.37) | PPARGPPARAPPARDF10HTR6 | |
| SCHEMBL4528222 | 0.81 | PPARG (0.37) | PPARGPPARAPPARDF10HTR6 | |
| SCHEMBL4526467 | 0.79 | PPARG (0.32) | PPARGPPARAPPARDOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1864984-A1 | TRICYCLIC SPIRO COMPOUND COMPRISING ACYL GROUP BOUND TO NITROGEN ATOM IN THE RING | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | KCNH1, SCN1A, SCN10A | PPARG 2153/4885PPARA 1675/4885PPARD 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.